Open an account

Harvard Bioscience

HBIO · NASDAQ

$8.34+$0.25 (+3.09%)TodayMarket closed ·
Prev close $8.09

About HBIO

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. The company is headquartered in Holliston, Massachusetts and currently employs 316 full-time employees. The company went IPO on 2013-10-21. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.

Employees
316
Headquarters
Holliston, Massachusetts
Listed
Oct 21, 2013
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
harvardbioscience.com

HBIO key statistics

Market cap
37.97M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
16.35K
Volume
23.43K
Open price
$7.99
High today
$8.38
Low today
$7.90
52 Week high
$9.40
52 Week low
$3.80

Harvard Bioscience (HBIO) at a glance

As of Oct 20, 2026, Harvard Bioscience (HBIO) shares are priced at $8.34, giving the company a market cap of 37.97M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $7.90 and $8.38. The current price is 5.6% above the day's low and 0.5% below its high.

Volume so far is 23.43K shares, above the average of 16.35K shares a day.

Over the past year Harvard Bioscience has ranged from $3.80 to $9.40, and now sits 81% of the way up that range.

Harvard Bioscience met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.14 per share against an estimate of -$0.2142.

The average analyst price target is $7.65, 8.3% below the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $7.65
Low
$7.57
Now
$8.34
High
$7.88

HBIO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 35.5% on average.

  1. Q3 FY24: reported -$0.20 per share against an estimate of $0.272
  2. Q4 FY24: reported $0.60 per share against an estimate of $0.51
  3. Q1 FY25: reported -$0.10 per share against an estimate of -$0.408
  4. Q2 FY25: reported -$0.10 per share against an estimate of -$0.102
  5. Q3 FY25: reported $0.00 per share against an estimate of $0.051
  6. Q4 FY25: reported $0.00 per share against an estimate of $0.357
  7. Q1 FY26: reported -$0.33 per share against an estimate of -$0.6324
  8. Q2 FY26: reported -$0.14 per share against an estimate of -$0.2142

HBIO news

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • Earnings Scheduled For November 6, 2025

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

Similar companies

Companies in the same industry as Harvard Bioscience

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.